In the article by P. A. Davol et al., titled “Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer,” which appeared in the October 15, 2003 issue of Cancer Research (pp. 6772–6783), Table 6 was omitted. Table 6 appears below.
In the article by H. M. Sowter et al., titled “Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia,” which appeared in the October 1, 2003 issue of Cancer Research (pp. 6130–6134), Raju Raval and John Moore’s middle initials were omitted. The correct author list is as follows: Heidi M. Sowter, Raju R. Raval, John W. Moore, Peter J. Ratcliffe, and Adrian L. Harris.
Multivariate cox models of RFS and DSS
. | RFS . | . | . | DSS . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|
Modelsa . | HR b . | (95% CI) . | P . | HR b . | (95% CI) . | P . | ||||
Base Model | ||||||||||
Nodal status | 6.4 | (1.7–24) | 0.006 | 11 | (1.5–84) | 0.019 | ||||
Tumor stage | 5.4 | (0.75–39) | 0.095 | 10 | (1.03–100) | 0.047 | ||||
Therapy | 6.1 | (0.88–42 | 0.068 | 5.7 | (0.45–72) | 0.095 | ||||
with SRcont | ||||||||||
Shc Ratio | 12.7 | (1.7–93) | 0.012 | 28.3 | (2.2–370) | 0.011 | ||||
Nodal status | 8.2 | (2.5–27) | 0.001 | 9.0 | (1.9–43) | 0.006 | ||||
Therapy | 6.7 | (0.98–45) | 0.053 | 10 | (0.75–132) | 0.081 | ||||
with SRcat | ||||||||||
Shc Ratiolow/high | 0.088 | (0.011–0.72) | 0.024 | |||||||
Shc Ratiointer/high | 0.20 | (0.050–0.83 | 0.029 | |||||||
Nodal status | 3.6 | (1.05–12) | 0.042 | |||||||
Therapy | 5.7 | (0.84–38) | 0.074 |
. | RFS . | . | . | DSS . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|
Modelsa . | HR b . | (95% CI) . | P . | HR b . | (95% CI) . | P . | ||||
Base Model | ||||||||||
Nodal status | 6.4 | (1.7–24) | 0.006 | 11 | (1.5–84) | 0.019 | ||||
Tumor stage | 5.4 | (0.75–39) | 0.095 | 10 | (1.03–100) | 0.047 | ||||
Therapy | 6.1 | (0.88–42 | 0.068 | 5.7 | (0.45–72) | 0.095 | ||||
with SRcont | ||||||||||
Shc Ratio | 12.7 | (1.7–93) | 0.012 | 28.3 | (2.2–370) | 0.011 | ||||
Nodal status | 8.2 | (2.5–27) | 0.001 | 9.0 | (1.9–43) | 0.006 | ||||
Therapy | 6.7 | (0.98–45) | 0.053 | 10 | (0.75–132) | 0.081 | ||||
with SRcat | ||||||||||
Shc Ratiolow/high | 0.088 | (0.011–0.72) | 0.024 | |||||||
Shc Ratiointer/high | 0.20 | (0.050–0.83 | 0.029 | |||||||
Nodal status | 3.6 | (1.05–12) | 0.042 | |||||||
Therapy | 5.7 | (0.84–38) | 0.074 |
a Model development is described in Methods. Wald-test values of P < 0.05 are indicated in bold type. Models use the Shc Ratio as an indexed categorical variable (SRcat) (see Table 4), and also as a continuous variable (SRcont).
b HR for SRcat compares the hazard of low to high and intermediate (inter) to high, as in Table 4. HR for SRcont reflects the full observed range of Shc Ratios. HR compares >3 positive nodes to 0 positive nodes: Stage III to Stage I; T4 to T1; for Therapy, surgery with radiation to surgery alone.